CD274 and triple-negative breast carcinoma: Interestingly, Deng et al. showed that targeting CDK5, an upstream regulator of PD-L1 transcription, via CRISPR also led to a significant reduction in PD-L1 levels in murine melanoma, lung metastasis, and in triple-negative breast cancer, indicating that both direct and indirect CRISPR strategies are viable [77].